- Rory Watson
- 1Brussels
The decision by the incoming European Commission president, Jean-Claude Juncker, to transfer responsibility for health technology, pharmaceuticals, and the European Medicines Agency over the next five years away from the commission’s health directorate to its industry counterpart has provoked an outcry from public health professionals.
The transfer reverses the decision by Juncker’s predecessor, Jose Manuel Barroso, five years ago to move the drugs and medical devices brief and the medicines agency away from the industry directorate to health. The U turn has prompted fears that business considerations will weigh more heavily than medical ones when future legislation or drug authorisation is being considered.
The …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.